Henlius and Runxin Biotech reached an exclusive license cooperation on BRAF V600E inhibitor, diversified innovation and upgraded

us" style='margin:0.

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;">

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;">

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;">

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

us" style="margin:10px 0px;padding:0px;max-width:100%;box-sizing:border-box;overflow-wrap:break-word ;">6;">

    

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

6;">

    

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

    

On March 29, 2021, Henlius International (2696.
HK) announced that it has reached an exclusive license agreement with Suzhou Runxin Biotechnology Co.
, Ltd.
(Runxin Bio) on the BRAF V600E inhibitor RX208, and Henlius has obtained the product The exclusive right to conduct research, development, production and commercialization in China (including Hong Kong, Macau and Taiwan).
Runxin Bio will receive a down payment of 97.
5 million yuan, up to about 1.
08 billion yuan in related clinical development, registration and sales milestone payments, as well as sales commissions after the product is launched.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.

This cooperation is an important strategic layout for Henlius to accelerate its diversified innovation.
It is expected to enhance the diversity of product targets and types, complement each other with Fuhong Henlius’s self-developed drugs, and further improve the existing innovation pipeline.
us" style='margin:0px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:16px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>

us" style='margin:0px 0px 10px;padding:0px;max-width:100%;box-sizing:border-box;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:16px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;overflow-wrap:break-word ;'>8;letter-spacing:0.
2px;">

BRAF protein is an important upstream regulator in the MAPK/ERK signaling pathway.
Its V600E mutation can activate the downstream MEK protein and further cause tumor cell growth, proliferation and invasion.

It is prone to occur in colorectal cancer, thyroid cancer, melanoma and other cancer Among them, this type of patients tends to have a poor prognosis.
Among them, colorectal cancer is the second most common malignant tumor in China .
There are about 555,000 new patients in 2020 ^[1] , and 5-15% of them have this mutation ^[2] .

The BRAF target product RX208 of this cooperation has a brand-new chemical core structure.
Preclinical research results show that the product has significant tumor suppressor activity and good safety.

The product is currently in clinical phase I, and early clinical studies have also shown preliminary efficacy with low side effects.

8;letter-spacing:0.

The BRAF target product RX208 of this cooperation has a brand-new chemical core structure.
Preclinical research results show that the product has significant tumor suppressor activity and good safety.

The product is currently in clinical phase I, and early clinical studies have also shown preliminary efficacy with low side effects.

BRAF protein is an important upstream regulator in the MAPK/ERK signaling pathway.
Its V600E mutation can activate the downstream MEK protein and further cause tumor cell growth, proliferation and invasion.
It is prone to occur in colorectal cancer, thyroid cancer, melanoma and other cancer Among them, this type of patients tends to have a poor prognosis.
Among them, colorectal cancer is the second most common malignant tumor in China .
There are about 555,000 new patients in 2020 ^[1] , and 5-15% of them have this mutation ^[2] .
Studies have shown that BRAF V600E inhibitor combined with EGFR monoclonal antibody can effectively improve the survival status and prognosis of such patients.
Currently, BRAF V600E inhibitors have been marketed for the treatment of colorectal cancer, melanoma, and rare disease lipid granuloma (Erdheim-Chester Disease, ECD).

^{[1] [1]} [1] ^{[2] [2]} [2]

The BRAF target product RX208 of this cooperation has a brand-new chemical core structure.
Preclinical research results show that the product has significant tumor suppressor activity and good safety.
The product is currently in clinical phase I, and early clinical studies have also shown preliminary efficacy with low side effects.

It is expected to become a Best-in-Class BRAF V600E small molecule inhibitor, and the target product has the potential to compete with Henlius’ EGFR.
, PD-1 target monoclonal antibody products have a synergistic effect, creating a better differentiated and innovative product portfolio in multiple cancer fields.